Skip to main content
. 2015 Sep 2;21(1):749–757. doi: 10.2119/molmed.2015.00197

Figure 2.

Figure 2

Identification of cathepsin V as a target for SQV and STO33438. (A) Effect of SQV and 334 on cathepsin V activity. (B) Dose-dependent inhibition of recombinant cathepsin V by SQV, 334, the cathepsin inhibitor, SID and the broad protease inhibitor E64. (C) Protein expression of cathepsin V and tubulin in human monocyte-derived macrophages transfected with control or cathepsin V siRNA. (D) Human monocyte-derived macrophages were transfected with control or cathepsin V siRNA and then assayed for HMGB1-dependent TNF-α production by ELISA. (E) Dose-dependent effect of the cathepsin inhibitor SID on HMGB1-induced TNF-α release from human monocyte derived macrophages. (F) Cytotoxicity was measured by LDH release into the cell media after 18 h of treatment.